This week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against an approval for the second time this year.
The med, called Albrioza in Europe and Relyvrio in the U.S., was shot down at CHMP—again—after a formal re-examination of the committee’s initial negative opinion in June.
Phase 2 data from its Centaur trial, which formed the basis of the FDA’s 2022 approval decision, didn’t sway the European regulators.
Now, the company is focused on its global phase 3 Pheonix study, which has an anticipated topline readout in mid-2024 and will provide further data on the drug’s efficacy and safety profile, Amylyx said in a statement.
The 48-week study has enrolled 664 participants across 69 sites in Europe and the U.S. If the data support an application, the company would try again for EU approval “as quickly as possible,” Amylyx said.
Meanwhile, after CHMP’s negative recommendation, it’s up to the European Commission to make the final call on the Albrioza application. The EC’s decision is expected by the end of 2023.
“ALS has no geographical boundaries, and we are working with urgency toward providing timely, broad, and sustainable access to AMX0035 for eligible people living with ALS who may benefit,” Amylyx’s co-CEOs Joshua Cohen and Justin Klee said in a statement.
In the U.S., the company won approval last September after overcoming several prior regulatory setbacks.
So far, Relyvrio is putting on a strong commercial show in the U.S., generating sales of $400 million since its launch. The med is priced at about $158,000 per year and has gained widespread insurance coverage, Amylyx execs have said.
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/07/13.jpg)
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)